Leede Jones Gab Weighs in on ProMIS Neurosciences, Inc.'s FY2024 Earnings (NASDAQ:PMN)Zolmax • 28 days ago
ProMIS Neurosciences, Inc. (NASDAQ:PMN - Free Report) - Leede Jones Gab cut their FY2024 EPS estimates for ProMIS Neurosciences in a research note issued to investors on Wednesday, April 3rd...
Share to Feed
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
ProMIS Neurosciences, Inc. (NASDAQ:PMN - Free Report) - Equities research analysts at Leede Jones Gab issued their FY2028 earnings per share (EPS) estimates for ProMIS Neurosciences in a research...
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE...
Adds Key U.S. and International Patent Allowances to Further Protect the Company's Monoclonal Antibody Therapeutic for the Treatment of Alzheimer's DiseaseCAMBRIDGE, Massachusetts and TORONTO...
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson's disease and Dementia with Lewy bodiesCAMBRIDGE, Massachusetts and TORONTO...
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to ShareholderProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company...
Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive OfficerCAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences...